<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895633</url>
  </required_header>
  <id_info>
    <org_study_id>2009-A00758-49</org_study_id>
    <nct_id>NCT02895633</nct_id>
  </id_info>
  <brief_title>Osteoarticular Tumor Characterization by Advanced Imaging</brief_title>
  <acronym>TUMOSTEO</acronym>
  <official_title>Osteoarticular Tumor Characterization by Advanced Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to compare and evaluate multiple functional imaging methods (perfusion,&#xD;
      diffusion, spectroscopy) for initial benign/malignant characterization of osteoarticular&#xD;
      tumors and to determine which method or which association of methods could improve non&#xD;
      invasive tissue characterization.&#xD;
&#xD;
      Secondary purposes are:&#xD;
&#xD;
        -  to determine a possible correlation between some parameters and the histological grade&#xD;
           (FNCLCC)&#xD;
&#xD;
        -  to suggest a coherent diagnostic imaging approach for osteoarticular tumors.&#xD;
&#xD;
      The ancillary study will enroll patients needing radiological tumor follow-up. The purpose is&#xD;
      to identify tools for evaluation of tumor activity and therapeutic response before&#xD;
      modification of morpho-volumetric data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients refered for the initial evaluation of suspected osteoarticular masses will be&#xD;
      included in this study after signing an informed consent.&#xD;
&#xD;
      Histologic analysis will be used as a gold standard.&#xD;
&#xD;
      The following imaging techniques will be evaluated:&#xD;
&#xD;
        -  contrast enhanced ultrasonography&#xD;
&#xD;
        -  Low dose CT perfusion&#xD;
&#xD;
        -  Magnetic resonance perfusion&#xD;
&#xD;
        -  Diffusion weighted imaging&#xD;
&#xD;
        -  Magnetic resonance proton spectroscopy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast enhancement in echography: yes or no</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast enhancement curve (absent, slow or fast) in echography</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal intensity of enhancement peak in echography</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean transit time of enhancement in echography</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gradient of contrast enhancement curve in echography</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascularization (dynamic analysis) in CT scanner</measure>
    <time_frame>baseline</time_frame>
    <description>0: absent&#xD;
1: low (&lt; 20UH)&#xD;
2: &gt; 20 UH without new blood vessels&#xD;
3: &gt; 20 UH and/or with new blood vessels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast enhancement curve (absent, slow or fast) in CT scanner</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal intensity of enhancement peak in CT scanner</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean transit time of enhancement in CT scanner</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gradient of contrast enhancement curve in CT scanner</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast enhancement curve (absent, slow or fast) in MRI</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal intensity of enhancement peak in MRI</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean transit time of enhancement in MRI</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gradient of contrast enhancement curve in MRI</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Choline peak in magnetic resonance spectroscopy</measure>
    <time_frame>baseline</time_frame>
    <description>Choline presence was defined as a clear metabolite peak at 3.2 ppm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent diffusion coefficient (ADC) in MR diffusion weighted imaging</measure>
    <time_frame>baseline</time_frame>
    <description>ADC value in mm2/s</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the perfusion curve in MRI</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perfusion curve gradient in MRI</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perfusion time-to-peak in MRI</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1090</enrollment>
  <condition>Bone Tumor</condition>
  <condition>Soft Tissue Tumor</condition>
  <arm_group>
    <arm_group_label>Patients with bone or peripheral soft-tissue tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ecography</intervention_name>
    <description>Standard Doppler ultrasound and perfusion imaging after injection of Sonovue</description>
    <arm_group_label>Patients with bone or peripheral soft-tissue tumor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CT scan</intervention_name>
    <description>With injection of Iomeron 400</description>
    <arm_group_label>Patients with bone or peripheral soft-tissue tumor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>With injection of gadolinium (Multihance)</description>
    <arm_group_label>Patients with bone or peripheral soft-tissue tumor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients examined for initial assessment of bone or peripheral soft-tissue primitive&#xD;
             tumor&#xD;
&#xD;
          -  patients with normal awareness level&#xD;
&#xD;
          -  patients having signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  persons deprived of liberty&#xD;
&#xD;
          -  persons under legal protection or unable to give informed consent&#xD;
&#xD;
          -  persons in life-threatening emergency&#xD;
&#xD;
          -  allergy to Sonovue, iodinated contrast media or gadolinium chelates&#xD;
&#xD;
          -  risk of pregnancy&#xD;
&#xD;
          -  breastfeeding women&#xD;
&#xD;
          -  acute coronary syndrome or unstable ischemic cardiopathy (ban on injection of contrast&#xD;
             agent for CT scan)&#xD;
&#xD;
          -  renal failure (ban on injection of contrast agent for MRI and CT scan)&#xD;
&#xD;
          -  contraindication to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Augusto GONDIM TEIXEIRA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Imagerie Guilloz, CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Augusto GONDIM TEIXEIRA</last_name>
    <email>ped_gt@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'Imagerie Guilloz, CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MR imaging</keyword>
  <keyword>Diffusion weighted imaging</keyword>
  <keyword>MR proton spectroscopy</keyword>
  <keyword>CT perfusion</keyword>
  <keyword>Contrast enhanced ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Soft Tissue Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

